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Purpose: Photodynamic therapy (PDT), the l ight activation of  photosensidzer dyes for 
the production of  oxygen and other free radical moieties without the generation of  heat, 
has been shown to inhibit  the  development of  experimentally induced intimal hyperpla- 
sia. The host response to PDT, a form of  vascular injury that results in complete vascular 
wall cell eradication, is devoid of  inflammation and proliferation and promotes favorable 
vascular wall healing. These effects do not result in intimal hyperplasia and are suggestive 
of  PDT-induced changes in the extraceUular matrix (ECM). As a model to better 
tmderstand the biologic consequences of PDT on the vascular wall matrix proteins, the 
effect of  PDT was studied on the powerful matrix-resident mitogen basic fibroblast factor 
(bFGF) in vitro. 
Methods: PDT (5 to 200 J / cm 2, 100 mW/cm 2, 675 nm) was used with the photosensi- 
tizer chloroaluminum sulfonated phthalocyanine (5 Ixg/ml) to inactivate bFGF in vitro 
while 100 J / cm 2 of  irradiation was administered 24 hours after 5 mg/ml  of  the 
photosensitizer was used in vivo. PDT was used on bFGF in solution and on endothelial 
cell- derived ECM. Enzyme-l inked immunosorbent assay was used to quantitate bFGF in 
solution after PDT treamaent or after extraction from the ECM by collagenase and heparin. 
Functional activity of  matrix-associated bFGF was assessed by smooth muscle cell mitogene- 
sis by 3H-thymidine incorporation. To demonstrate he in vivo relevance of these observa- 
tions, immunohistochemical analysis of  PDT-treated rat carotid arteries was undertaken. 
Results: PDT eliminated etectable vels of  bFGF in solution. PDT of  ECM significantly 
reduced matr ix-bound bFGF (1.0 4- 0.6 vs 27.5 4- 1.3 pg /ml ;  p < 0.0001). This 
reduction in bFGF after PDT of  the ECM was associated with a decrease in vascular 
smooth muscle cell mitogenesis (52.4% 4- 4.6%; p < 0.0001) when plated on PDT-treated 
matrix compared with nontreated matrix. Quantitative replenishment of exogenous 
bFGF to PDT-treated matrix restored proliferation to baseline levels. PDT of  rat carotid 
arteries demonstrated a loss of  bFGF staining compared with control nontreated arteries. 
Conclusions: PDT inactivation of  matrix-resident bFGF and possibly other bioactive 
molecules can provide a mechanism by which PDT suppresses mooth muscle cell 
proliferation in the vessel wall. This free radical-mediated alteration of  matrix may 
contribute to favorable vascular healing when PDT is used for the inhibit ion of  injury- 
induced intimal hyperplasia. (J Vasc Surg 1997;26:294-301.) 
Restenosis as a result o f  intimal hyperplasia (IH) 
l imits the effectiveness o f  surgical and catheter-based 
procedures to alleviate the life- and l imb-threatening 
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of novel experimental strategies including: (1) anti- 
sense oligonucleotides for inhibition of cell-cycle 
regulatory mRNA translation3; (2) antibodies to 
growth factors4; (3) gamma ionizing radiation5; and 
(4) photodynamic therapy (PDT). 6,7 
PDT involves the administration f an otherwise 
biologically nontoxic photosensitizer dye that has a 
proclivity to concentrate in tissue that contains pro- 
liferating cells, including balloon-injured arteries. 8 
Only with local absorption of light by the photosen- 
sitizer over the area of interest is there generation of 
free radicals without he production of heat. 9 The 
activated photosensitizer can alone, or in the pres- 
ence of 02, by generating oxygen free radicals, exert 
local cytotoxic effects by damaging the cell constitu- 
ents, such as membranes and other organelles. 1°,11 
It has been clearly documented that PDT can 
inhibit experimental IH in vivo. 6,7 It is a paradox that 
PDT, while causing complete radication of cells in 
the vessel wall, does not elicit a biologic response 
common to other forms of vascular wall injury. Mi- 
croscopic assessment of balloon-injured arteries ub- 
jected to the proper PDT dosimetry demonstrates an 
inhibition of experimental IH, an absence of inflam- 
mation or aneurysmal dilatation, and rapid repopula- 
tion of the adventitia with myofibroblasts and the 
intima with endothelium. After PDT, there is mini- 
mal repopulation of the media with smooth muscle 
cells (SMCs) and no increased SMC proliferation or 
migration at the boundary between PDT-treated and 
untreated artery. 7 These consistent observations after 
PDT treatment constitute a favorable vascular "heal- 
ing" response and are a unique response to a form of 
vascular injury. The mechanisms of this PDT effect 
on the vascular wall are, however, not understood. 
Complex interactions between cells, growth fac- 
tors, and extracellular matrix (ECM) are responsible 
for healing in tissues. 12,13 This study hypothesizes 
that alterations in ECM and matrix-bound growth 
factors after PDT treatment ofthe arterial wall result 
in the favorable responses observed: reendothelial- 
ization of the intima and inhibition of SMC prolifer- 
ation. To further investigate this question, basic fi- 
broblast growth factor (bFGF) was chosen as a 
model of bioactive molecules that PDT treatment 
may affect on ECM) 4,~5 bFGF was chosen because it
is a powerful matrix-resident mitogen and has been 
implicated as the major primary initiator f SMC 
replication after vascular injury. 16 
The studies herein describe and quantify the abil- 
ity of PDT to alter bFGF in solution and on acellular 
endothelial cell (EC)-derived ECM. The quantita- 
tive changes in the matrix-associated growth factor, 
bFGF, were further correlated with the functional 
effect on SMC proliferation. Finally, the effect of 
PDT on ECM was evaluated invivo using immuno- 
histochemical analysis. 
MATERIALS AND METHODS 
Cell cultures. Primary cultures of bovine aortic 
ECs and SMCs were established with cell type verifi- 
cation as previously described. 25Cells were kept in a 
37 ° C, 5% CO 2 incubator, efed every 48 to 72 hours 
with complete Dulbecco's modified Eagle's medium 
(Gibco) supplemented with 10% defined bovine calf 
serum, and penicillin (100 U/ml), streptomycin 
(100 mg/ml), and 0.6 mmol/L L-glutamine 
(Gibco), and passed at 1:5 ratios using 0.05% Tryp- 
sin/0.125% ethylenediamine t traacetic acid on 
reaching confluence. Passage 2 to 5 cell cultures were 
used for all experiments. 
Matrix preparations. ECs were plated in six- 
well tissue culture plates (Falcon, Becton Dickinson) 
at densities of 5 × 10 s cells/well, maintained in 
confluence for 7 to 9 days, and removed with 0.5% 
Triton X-100 (Sigma Chemical) and 20 mmol/L 
NH4OH for 30 minutes. This procedure provided 
cell culture plates that were covered by ECM with 
intact associated growth factors, la The matrix plates 
were stored at 4 ° C and were used within 48 hours. 
Laser irradiation. Laser irradiation was per~ 
formed using an argon-pumped dye laser (Coherent 
INNOVA I 100 and Coherent CR 599, Coherent) 
tuned at 675 nm and delivering an end-fiber, ther- 
moneutral irradiance of 50 mW/cm 2for a total flu- 
ence of 100 J/cm 2 unless otherwise specified. For 
PDT, the photosensitizer dye chloroaluminum sulfo- 
hated phthalocyanine (CASPc; 5 ~g/ml) in phos- 
phate-buffered saline solution was added to ECM 
immediately before irradiation or was incubated for 2 
hours as a drug-only control. 
PDT of soluble bFGF. Recombinant human 
bFGF (I ng; R & D Systems) in 0.1% protease-free 
bovine serum albumin (Sigma Chemical) was added 
to 5 mg/ml of CASPc and irradiated insolution with 
fluences of 5 to 200 J/cm 2. The assays for bFGF 
were immediately performed in the dark, and the 
results were expressed as the percent bFGF inactiva- 
tion of initial concentration. 
Cellular proliferation assay. To determine the 
functional significance of the measured bFGF con- 
centrations in the ECM, SMC proliferation assays 
were performed. SMCs were seeded on matrix plates 
at 1 x 105 cells/well in 0.5% calf serum and incu- 
bated for 24 hours. Two and halfmCi 3H-thymidine 
(New England Nuclear) was added to the medium 
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Fig. 1. PDT inactivation of soluble bFGF (l ng/mi). Percent of bFGF remaining after 
inactivation by PDT is plotted versus fluence administered. Values are mean _+ SEM of three 
experiments in triplicate. *p < 0.00I versus initial concentration. :~p < 0.02 versus 5 J/cm 2. 
and incubated with the cells for 5 hours. The plates 
were rinsed twice with phosphate-buffered saline so- 
lution and trypsinized. The cell number was verified 
using a hemocytometer before quantifying the 3H- 
thymidine incorporation with a scintillation counter 
(Beckman Instruments). Results were calculated 
from the counts/cell × min -1 versus control. 
Extraction o f  matrix-associated bFGF. After 
matrix preparation, bFGF was extracted from the 
ECM by incubating with 0.1% CLS II collagenase 
(Worthington) at 37 ° C in phosphate-buffered saline 
solution and Ca/Mg supplemented with heparin 
(100 mg/rnl, Sigma Chemical) and bovine serum 
albumin (0.1%) for 2 hours, bFGF determinations of 
these extracts were immediately undertaken. 
bFGF assay. Determinations of bFGF concen- 
trations were performed with a commercially avail- 
able enzyme-linked immunosorbent assay (ELISA) 
kit (Quantikine P,,&D Systems), which uses the 
"sandwich" enzyme immunoassay technique using 
200 ml of extracts and comparing the data with a 
standard curve. 
Extraction efficiency o f  bFGF (EE%). To de- 
termine the fficiency of bFGF extraction, a lmown 
amount of  bFGF was incubated with untreated ma- 
trix for 2 hours. The extraction efficiency was calcu- 
lated using this formula: 
EE(%) = Fx/([FA + ~] -Fs~, )  x 100 
where F x equals the amount of bFGF extracted from 
the matrix; F a equals the concentration of  bFGF 
added; F M equals the concentration of bFGF in si- 
multaneously prepared control matrix; and Fsu e 
equals the bFGF that remains in the supernatant after 
a 2-hour incubation period. 
Matrix a i~ i ty  o f  bFGF (AF%). To determine 
how avidly bFGF binds to matrix, a lmown amount 
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Fig. 2. PDT inactivation of ECM-bound bFGF. Concentration of bFGF (pg/ml) extracted 
from matrix (9.6 cm 2 plate) is plotted for PDT-treated and control matrices: matrix (untreat- 
ed), CASPc (drug-only), or light (laser-only). Values are mean _+ SEM of two experiments in 
triplicate. *p < 0.0001 versus matrix. 
ofbFGF was added to the control or PDT matrix and 
extracted, and the binding ofbFGF to the ECM was 
calculated using this formula: 
AF(%) = ( [Fx -Fsuv] / [Fa  + FM]) X 100 
Immunohistochemical  analysis. Four Sprague- 
Dawley rats (Charles River Breeding Laboratories) 
were anaesthetized with intramuscular ketamine (35 
mg/kg),  atropine (40 Ixg/kg), and xylazine (5 mg/  
kg). The common carotid artery was exposed 24 
hours after intravenous administration of CASPc (5 
mg/kg)  and irradiated with 100 mW/cm 2 for 100 
J / cm 2 at 675 nm for PDT administration as previ- 
ously described. 7 The animals were immediately 
killed, and the carotid arteries were harvested, gently 
rinsed in saline solution, and frozen in Tissue Tek 
OCT (Miles, Inc) for processing. Animal care was in 
strict compliance with "Principles of  Laboratory An- 
imal Care" and the Guide for the Care and Use of 
Laboratory Animals (NIH Publication No. 86-23, 
revised 1985) and approved by an institutional ani- 
mal care committee. 
Monoclonal antibody to bFGF (Zymogenetics) 
was used to characterize the presence of bFGF in 4 
txm cryosections of carotid arteries using thc two- 
layer indirect immunoperoxidase t chnique previ- 
ously described. 19 Briefly, the primary antibody (1: 
1000) was labeled by biotinylated horse antimouse 
immunoglobulin (Vector Laboratories) and counter- 
stained with nuclear fast red (Sigma Chemical). Un- 
treated arteries were used as a positive control, and 
arteries stained with nonspecific primary antibody 
were used as negative controls to exclude nonspecific 
binding by the primary or secondary antibody. 
Statistics. MI data are expressed as mean - 
SEM. Data comparisons of the matrix affinity of 
bFGF were performed using a two-tailed Student's t 
test for independent variables with Bonferroni cor- 
rection. Comparisons between groups were per- 
formed with a one-way analysis of variance with 
Tukey's post hoc test. p values less than 0.05 were 
considered significant. 
RESULTS 
In vitro destruction of  bFGF. PDT readily 
eliminated detectable levels of bFGF in solution by 
ELISA measurements. There was ahnost a 90% loss 
of measurable bFGF by as little as 5 J / cm 2 of PDT 
(Fig. 1). Administered fluences of 50, 100, and 200 
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Fig. 3. PDT inhibition of ECM proliferative stimulus on SMCs. Proliferative stimulus of ECM 
on SMCs, assessed by 3H-thymidine incorporation, is plotted for PDT-treated and control 
matrices: matrix (untreated), CASPc (drug-only), or light (laser-only). To determine whether 
proliferative stimulus of ECM could be restored after PDT, bFGF (500 pg) was incubated with 
untreated and PDT matrix before addition fSMC s (+ bFGF). Values are mean _ SEM of three 
experiments in triplicate. *p < 0.0001 versus matrix. 
J / cm 2 were not significantly different in their ability 
to inactivate the bFGF in solution, 
These results indicated that free bFGF was ex- 
quisitely sensitive to PDT. However, it was possible 
that matrix-associated bFGF would not have been 
similarly affected because of the presence of  numer- 
ous other proteins that can be targets of PDT-gener- 
ated free radicals. Therefore, it was necessary to 
quantitate the effect of PDT on matrix-bound bFGF. 
PDT of  ECM resulted in barely detectable l vels of 
bFGF compared with untreated ECM (1.0 .+ 0.6 vs 
27.5 + 1.3 pg/ml;  n = 6; p < 0.0001) by ELISA. 
The amount of bFGF in untreated control ECM was 
equivalent to the amount in matrix treated with drug 
only or light only (Fig. 2). 
Extraction efficiency o f  bFGF. To determine 
how much bFGF was actually extracted from the 
untreated matrices, known amounts of bFGF were 
added. The extraction efficiency of the assay was 
calculated (formula 1) and found to be 52% + 2% 
(n = 9). 
Matrix affinity o f  bFGF. To determine 
whether bFGF binding sites were altered by PDT, 
the amount of  adsorbed bFGF to PDT and untreated 
matrix was measured. Untreated matrix only ad- 
sorbed 59% + 1% of added bFGF. In contrast, PDT- 
treated matrix adsorbed 81% + 2% (n = 6; p < 
0.001) of exogenously added bFGF. This finding 
suggests that untreated matrix has less capacity to 
adsorb exogenously added bFGF. 
Matrix effects on SMC proliferation. The 
functional assay of PDT effects on matrix were inves- 
tigated by SMC proliferation, aH-thymidine incor- 
poration by SMCs was studied after the matrix was 
exposed to: (1) PDT; (2) untreated matrix control; 
(3) laser light control; or (4) CASPc drug control. 
SMCs plated onto PDT-treated matrix had markedly 
less proliferation (52.4% + 4.6%; p < 0.0001 vs 
matrix control, n = 9). Light only and drug only did 
not significantly alter the proliferation of SMCs on 
ECM when compared with untreated ECM (Fig. 3). 
Quantitative replenishment of the bFGF inacti- 
vated by PDT of the matrix restored the proliferative 
response of the ECM to SMCs. The amount of 
bFGF (500 pg) incubated with PDT matrix for res- 
toration of SMC proliferation was extrapolated from 
the bFGF extraction of untreated ECM, the extrac- 
tion efficiency, and the bFGF binding affinity to PDT 
ECM. Incubation and removal of  bFGF to PDT- 
treated matrix before cellular seeding did restore 
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SMC proliferation to levels comparable with those of 
control untreated matrix. The addition of bFGF to 
untreated matrix increased proliferation above that 
of control matrix (Fig. 3). 
In vivo destruction of  bFGF. Immunohisto- 
chemical staining of untreated arteries with antibody 
to bFGF demonstrated positive staining of the intima 
and irregular positive clumping of the media but 
little to no staining of the adventitia (Fig. 4). The 
specimens that were not exposed to the primary 
antibody (negative control, data not shown) only 
displayed counterstaining of the nuclei with nuclear- 
fast red. Immunohistochemical analysis of the PDT 
arteries did not demonstrate any evidence of bFGF 
staining in the intima, media, or adventitia, but there 
was evidence of nuclear-fast red staining of the nuclei 
in the media (Fig. 4). 
DISCUSSION 
As a concept, the combined use of light and a 
photosensitizer to produce cytotoxic effects is not 
new. The ability of PDT to eradicate malignant tu- 
mors or other proliferating tissues has recently re- 
ceived substantial ttention. Clinical trials have been 
initiated using PDT to treat squamous cell carcino- 
mas, mesotheliomas, retinoblastomas, ovarian can- 
cer, and recurrent bladder carcinomas. 2°Although 
cellular eradication of neoplasms has been the major 
focus of PDT research, there is an increased interest 
in its application to other disease states of cellular 
proliferation, such as IH. 6 
It is a paradox that PDT, which inherently causes 
injury, can successfully inhibit IH after another injury 
to the vessel wall. That this can be successfully 
achieved in vivo is intriguing and raises many inter- 
esting mechanistic questions. In our laboratory and 
others,  21-23 the emphasis has been focused on the 
successful ability of PDT to eradicate SMC effector 
cells in the vessel wall, which normally proliferate 
after injury to cause IH. Despite complete cellular 
eradication, an interesting histologic observation 
noted was that there was no SMC or other cellular 
repopulation i  the media, 6 leaving it appearing in- 
ert. At the boundary area between treated (i.e., erad- 
icated SMCs) and untreated tissue, there was no 
evidence of increased proliferation. 7 These unique 
findings after PDT of the vascular wall suggest inher- 
ent changes in the ECM wall, which was investigated 
in this study. 
No major changes have been noted after PDT in 
the structural matrix by histologic stains, electron 
microscopy, 6 immunohistochemical analysis of struc- 
tural proteins, ~7 or increased artery wall compliance 
Fig. 4. Immunohistochemical micrographs (original mag- 
nification, 200x) of rat common carotid arteries depict 
bFGF by immunoperoxidase staining and counterstained 
with nuclear-fast red. A, Control artery with inrimal and 
medial staining of bFGF. B, PDT artery immediately after 
in vivo treatment with no evidence of staining for bFGF. 
Bar represents 50 mm. 
that could lead to aneurysm formation. 24 This study 
was therefore directed towards the effect of PDT on 
bioactive molecules, uch as growth factors known to 
be resident in the ECM. 
Many peptide growth factors, such as bFGF and 
PDGF, have been implicated as mediators of vascular 
cell proliferation. 25,26 Although PDGF and other 
proliferative secretory proteins are released by live 
cells or platelets 27 and have a role in IH, bFGF is a 
powerful, nonsecretory, matrix-resident mitogen 
that is known to be one of the initiators of IH .  26 
Mechanically injured EC have been shown to release 
bFGF, 3° which can bind to ECM and provide a 
prolonged stimulus for SMC proliferation. 29,3° Also, 
because antibodies to bFGF inhibit the development 
of IH, 16 this study concentrated on the investigation 
of PDT effects on ECM using bFGF as a model. 
Initial studies indicated that free bFGF was ex- 
quisitely sensitive to PDT. PDT also inactivates 
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bFGF bound to the ECM in vitro. Because drug- 
only and light-only had no significant effect on bFGF 
content and there are no thermal effects at these low 
irradiances, these data suggest that the production of 
free radical moieties by PDT was critical to inactiva- 
tion of bFGF. The failure to detect bFGF after PDT 
of the ECM could be interpreted as its complete 
inactivation or alteration of the binding sites, render- 
ing the growth factor unextractable. The addition of 
exogenous bFGF to PDT and untreated control ma- 
trix demonstrated that PDT matrix adsorbed a signif- 
icantly greater amount of exogenous bFGF, suggest- 
ing that its bFGF matrix-binding sites (heparin 
sulfates) were unoccupied and functional. These 
findings firmly implicate the PDT inactivation of 
bFGF, but not the matrix-associated heparin sulfate 
binding sites. These findings concur with prior ob- 
servations that PDT effects primarily proteins by free 
radical affinity for the amino acids, such as trypto- 
phan and cysteine, that contain unsaturated bonds 
and not polysaccharide moieties. 11 
In addition to the ELISA measurements, the 
functional significance of the bFGF eradication was 
investigated by SMC proliferation. Decreased SMC 
proliferation on PDT-treated matrix may result from 
direct loss of matrix-bound bFGF and other bioac- 
five molecules that stimulate SMC growth. By inac- 
tivating bFGF, the amplification of SMC prolifera- 
tion by extracellular bFGF, known to induce mRNA 
for further bFGF synthesis, would not occur. 32 The 
ability to recover SMC proliferation by the quantita- 
tive replenishment of exogenous bFGF to PDT 
ECM underlines the importance of PDT effects on 
ECM components such as the growth factor, bFGF. 
There is no evidence that this PDT effect would 
be specific to bFGF. PDT generates free radicals, 
which have been shown to alter many proteins, and 
our laboratory has described PDT inactivation of 
transforming rowth factor-J3 activity in vitroY 
Therefore, it is highly likely that PDT-generated free 
radicals target multiple ECM molecnles even though 
they may have different sensitivities to these reactive 
species. However, the cumulative ffect of these free 
radicals has been shown to alter the healing response 
of vessels after injury. 
The inactivation of bFGF can, in part, explain the 
decreased SMC proliferation oted in vitro. How- 
ever, recent data from this laboratory have demon- 
strated that this inhibitory effect of PDT matrix on 
SMC is not a general effect on all cells, because EC 
proliferation is not inhibited but enhanced on PDT- 
treated ECM compared with control. 17 This may 
therefore be mediated by a different mechanism, the 
inactivation of the multifunctional cytokine TGF-~3 
(Statius van Eps et al., unpublished ata). PDT, by 
affecting both the stimulatory and inhibitory mole- 
cules such as bFGF and TGF-[~ found in ECM, may 
result in differential effects on vascular cell functions 
depending on its ultimate ffect on the multiple bio- 
logically active molecules in the ECM. 
To validate the in vivo relevance of these in vitro 
observations, qualitative immunohistochemical as-
sessment of the presence of bFGF was undertaken 
comparing normal and PDT-treated rat arteries. Us- 
ing PDT dosimetry known to inhibit IH in the bal- 
loon-injured Carotid artery model, 7no bFGF stain- 
ing could be identified in the artery wall immediately 
after PDT (Fig. 4). The immunohistochemical anal- 
ysis, therefore, emphasizes the biologic relevance of 
these findings, but no direct extrapolation can be 
made to the more complex human problem of clini- 
cal restenosis. 
This study provides data demonstrating how 
PDT can directly alter cell-derived ECM by inactivat- 
ing a matrix-resident growth factor, bFGF. In addi- 
tion, these data mark a radical departure from previ- 
ously published studies of PDT, which focus only on 
cytotoxicity and not on the ability of PDT to alter 
ECM or inactivate bioactive molecules that can alter 
cellular behavior and therefore the healing response. 
Although PDT-mediated cytotoxicity is important in 
the vascular system and other applications, the inac- 
tivation of bFGF and possibly other biologically ac- 
tive molecules in the ECM could be pivotal for pro- 
viding a connective tissue scaffold amenable to 
favorable reendothelialization while inhibiting IH. 
This interaction of PDT with ECM may also have 
relevance for cell growth and function in sites other 
than the vascular system and, therefore, provide fur- 
ther insight into the mechanisms of other prolifera- 
tive disorders. 
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